Company / R&D per Share
Corvus Pharmaceuticals, Inc. R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.32
FY2024
5-year range
$0.32 / $1.08
FY2020-FY2024
Trend
-7.6%
vs FY2023
Sector context
#185 of 207
Health Care
What the data says
Corvus Pharmaceuticals, Inc.'s r&d per share of $0.32 is lower than 89% of companies in the Health Care sector (FY2024). R&D per Share has declined for 7 consecutive years, from $2.26 in FY2017 to $0.32 in FY2024.
Based on SEC 10-K filings.
0.32 in FY2024 with a 5-year CAGR of -24.5%.
Declined from $0.53 to $0.32 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -23.0%
- 5-Year CAGR
- -24.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 207This company $0.32 Sector average $12.26
▼
-97.4% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s r&d per share has declined for 7 consecutive years.
- In FY2024, r&d per share decreased 7.6% year-over-year.
- Ranks #185 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.32 | -7.6% |
| FY2023 | $0.34 | -34.5% |
| FY2022 | $0.53 | -24.4% |
| FY2021 | $0.70 | -35.6% |
| FY2020 | $1.08 | -16.5% |
| FY2019 | $1.29 | -7.8% |
| FY2018 | $1.40 | -37.9% |
| FY2017 | $2.26 | +18.7% |
| FY2016 | $1.90 | -93.7% |
| FY2015 | $30.38 | +13514.1% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026